Nashville、TNにおける卵巣がんの臨床試験
Nashvilleとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する49件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
被験者募集中第2/3相
- Vanderbilt University/Ingram Cancer Center, Nashville
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of PHST001 in Advanced Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Tennessee Oncology, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
被験者募集中第2相
- SCRI Oncology Partners, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- SCRI Oncology Partners, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute (SCRI), Nashville
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
被験者募集中第2相
- SCRI Oncology Partners /ID# 279733, Nashville
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
被験者募集中第1相
- Research Site, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
被験者募集中観察研究
- Vanderbilt University Medical Center, Nashville
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
被験者募集中第2相
- Research Site, Nashville
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- Vanderbilt University Medical Center, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institue, Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
被験者募集中第1相
- Sarah Cannon - Tennessee Oncology, Nashville
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
被験者募集中第3相
- Henry-Joyce Cancer Clinic ( Site 0011), Nashville
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
被験者募集中第1/2相
- Sarah Cannon Nashville, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
被験者募集中第3相
- Henry-Joyce Cancer Clinic ( Site 0060), Nashville
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
被験者募集中第1相
- Normunity Investigational Site, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Vanderbilt University Medical Center, Nashville
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
被験者募集中
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
- Vanderbilt-Ingram Cancer Center at Franklin, Franklin · 17マイル先
- 他1件
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
- Vanderbilt-Ingram Cancer Center at Franklin, Franklin · 17マイル先
- 他1件
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- SCRI - TriStar Medical Group Children's Specialists, Nashville
- SCRI Oncology Partners, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Investigative Site #102, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
被験者募集中第2相
- SCRI Oncology Partners, Nashville
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- US Oncology Research LLC, Nashville
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
被験者募集中第3相
- Sarah Cannon Research Institute (Oncology Associates of Oregon PC), Nashville
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute (SCRI), Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- Vanderbilt University Medical Center, Nashville
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
被験者募集中第1相
- Tennessee Oncology, Nashville
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
被験者募集中第1/2相
- Research Site, Nashville
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
被験者募集中第3相
- Vanderbilt University Medical Center, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
被験者募集中観察研究健康なボランティア歓迎
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
被験者募集中第1/2相
- Tennessee Oncology, Nashville
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #6, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
- Pittsburgh, PA30件の研究
Nashvilleにおける他の研究
- 非小細胞肺癌97件の研究
- 乳がん81件の研究
- 転移性癌70件の研究
- 大腸癌69件の研究
- がん（全種類）65件の研究
- 前立腺がん43件の研究
- 肺がん40件の研究
- 頭頸部扁平上皮癌39件の研究
- 膵臓がん39件の研究
- 子宮内膜がん38件の研究
- 悪性黒色腫33件の研究
- 多発性骨髄腫32件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。